ADVISORY, Aug. 27, 2013 (GLOBE NEWSWIRE) --
Oramed Pharmaceuticals Inc. [ORMP], a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection, will visit the NASDAQ MarketSite in Times Square.In honor of the occasion, Nadav Kidron, CEO will ring the Closing Bell. Where: NASDAQ MarketSite – 4 Times Square – 43 rd & Broadway – Broadcast Studio When: Wednesday, August 28, 2013 – 3:45 p.m. to 4:00 p.m. ET Contact : Aviva Sherman 972 2-566-0001 firstname.lastname@example.org www.oramed.com NASDAQ MarketSite: Christine Barna (646) 441-5310 Christine.Barna@nasdaqomx.com Feed Information: Fiber Line (Encompass Waterfront): 4463 Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC 3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK Facebook and Twitter: For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at: http://www.facebook.com/NASDAQ . For news tweets, please visit our Twitter page at: http://twitter.com/nasdaqomx . Webcast: A live webcast of the NASDAQ Closing Bell will be available at: http://www.nasdaq.com/about/marketsitetowervideo.asx . Photos: To obtain a hi-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice. About Oramed Pharmaceuticals Inc. [ORMP]: Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed's technology is based on over 30 years of research by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801) currently initiating Phase 2 clinical trials on type 2 diabetic (T2DM) patients under an Investigational New Drug application with the U.S. Food and Drug Administration, and with its oral exenatide capsule (ORMD-0901; a GLP-1 analog), with trials on healthy volunteers (Phase 1b) and T2DM patients (Phase 2a) underway. Oramed is also moving forward with clinical trials of ORMD-0801 for the treatment of type 1 Diabetes The company's corporate and R&D headquarters are based in Jerusalem.